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Available online 26 May 2017Sodium-glucose cotransporter (SGLT) 2 inhibitors increase urinary glucose excretion (UGE), leading to blood glu-
cose reductions and weight loss. However, the impacts of SGLT2 inhibition on energy homeostasis and obesity-
induced insulin resistance are less well known. Here, we show that empagliﬂozin, a SGLT2 inhibitor, enhanced
energy expenditure and attenuated inﬂammation and insulin resistance in high-fat-diet-induced obese (DIO)
mice. C57BL/6Jmice were pair-fed a high-fat diet (HFD) or a HFDwith empagliﬂozin for 16weeks. Empagliﬂozin
administration increased UGE in the DIO mice, whereas it suppressed HFD-induced weight gain, insulin resis-
tance, and hepatic steatosis. Moreover, empagliﬂozin shifted energymetabolism towards fat utilization, elevated
AMP-activated protein kinase and acetyl-CoA carbolxylase phosphorylation in skeletalmuscle, and increased he-
patic and plasma ﬁbroblast growth factor 21 levels. Importantly, empagliﬂozin increased energy expenditure,
heat production, and the expression of uncoupling protein 1 in brown fat and in inguinal and epididymal
white adipose tissue (WAT). Furthermore, empagliﬂozin reduced M1-polarized macrophage accumulation
while inducing the anti-inﬂammatory M2 phenotype of macrophages within WAT and liver, lowering plasma
TNFα levels and attenuating obesity-related chronic inﬂammation. Thus, empagliﬂozin suppressed weight gain
by enhancing fat utilization and browning and attenuated obesity-induced inﬂammation and insulin resistance
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As the global rate of obesity has more than doubled in recent de-
cades, the rates of associated metabolic disorders, including diabetes,













s an open access article underhave also increased markedly. Low-grade sustained inﬂammation
links obesity to insulin resistance and its comorbidities, such as type 2
diabetes and NAFLD (Hotamisligil, 2006; Sell et al., 2012). Excessive
fat accumulation increases the inﬁltration of proinﬂammatory immune
cells into metabolic tissues and causes phenotypic shifts in macro-
phages, leading to the development of insulin resistance (Lumeng et
al., 2007; Weisberg et al., 2003). However, therapeutic approaches for
improving systemic energy balance and chronic inﬂammation in obesi-
ty are limited.
Sodiumglucose cotransporter-2 (SGLT2) inhibitors have emerged as
a promising new class of glucose-lowering drugs for themanagement of
type 2 diabetes. SGLT2 inhibitors increase urinary glucose excretion
(UGE), thereby reducing hyperglycaemia and weight with apparent
pleiotropic effects (Ferrannini and Solini, 2012; Inzucchi et al., 2015).
When large amounts of glucose are forced into urinary excretion pro-
cesses, whole-body metabolism undergoes adaptive changes involving
glucose ﬂuxes, hormonal responses, and fuel selection (Rossetti et al.,
1987). Recent clinical studies have shown that the treatment of type 2
diabetes with SGLT2 inhibitors paradoxically increases endogenousthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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hyperglycaemia (Ferrannini et al., 2014; Merovci et al., 2014). More-
over, the chronic administration of empagliﬂozin drives a fuel shift in
which tissue glucose disposal decreases, and lipid use increases
(Ferrannini et al., 2016; Ferrannini et al., 2014), although the mecha-
nisms underlying these effects have yet to be determined.
These observations indicate a uniquemode of action of SGLT2 inhib-
itors in which they operate independently of the insulin pathway and
yield favourable effects on obesity, ectopic fat accumulation and comor-
bidities such as insulin resistance and NAFLD. However, the effects of
SGLT2 inhibition on energy homeostasis and obesity-associated inﬂam-
mation remain largely unknown. Therefore, this study aimed to exam-
ine the effects of the SGLT2 inhibitor empagliﬂozin on systemic energy
balance and chronic inﬂammation in high-fat-diet (HFD)-induced
obese (DIO) mice.
2. Materials and Methods
2.1. Animals and Diets
Eight-week-old male C57BL/6J mice (Hamamatsu, Japan) were ran-
domly divided into four groups and pair-fed for 16weeks as follows: (1)
normal chow (NC) with 10% of calories from fat (CRF-1, Charles River
Laboratories, Wilmington, MA); (2) HFD with 60% of calories from fat
(D12492, Research Diets, New Brunswick, NJ); (3) HFD with 0.003%
(w/w) empagliﬂozin (Boehringer Ingelheim Pharma GmbH & Co. KG,
Biberach an der Riss, Germany; HFD + Lo Empa, equivalent to
3 mg/kg bodyweight); or (4) HFD with 0.01% (w/w) empagliﬂozin
(HFD + Hi Empa, equivalent to 10 mg/kg bodyweight). All animal pro-
cedures were performed in accordance with the standards set forth in
the Guidelines for the Care and Use of Laboratory Animals at Kanazawa
University, Japan.
2.2. Indirect Calorimetry
After 6 weeks of feeding, the mice were housed individually in indi-
rect calorimeter chambers (Oxymax; Columbus Instruments, Columbus,
OH). Calorimetry, daily body weights, and daily food intake data were
measured during a 3-day acclimation period followed by a 2-day exper-
imental period. Oxygen consumption (VO2), carbon dioxide production
(VCO2), and respiratory exchange ratio (RER, VCO2/VO2) were evaluat-
ed for 2 consecutive days. Energy expenditurewas calculated by the for-
mula as energy expenditure = VO2 × [3.815 + (1.232 × RER)] and
normalized to the body mass of each subject. Rectal temperature was
measured on 3 consecutive days between 9 and 10 am using a micro-
probe thermometer (Physitemp Instruments, Clifton, NJ).
2.3. Fluorescence-activated Cell Sorting (FACS)
Cells from the liver and epididymal white adipose tissue (eWAT)
were prepared as previously described (Kitade et al., 2012; Ni et al.,
2015a). The isolated cells were incubated with Fc-Block (BD Bioscience,
San Jose, CA), followed by incubation with ﬂuorochrome-conjugated
antibodies (Supplementary Table 1). Flow cytometry was performed
using a FACSAria II (BD Bioscience), and the data were analysed using
the FlowJo software (Tree Star, Ashland, OR).
2.4. Immunohistochemistry
Parafﬁn-embedded eWAT, liver, and brown adipose tissue (BAT)
sections were immunohistochemically stained for F4/80 and
uncoupling protein (UCP) 1 as previously described (Brestoff et al.,
2015; Zhuge et al., 2016). The quantiﬁcation of the positive area were
calculated by ImageJ software (Version 1.50). The pancreas was stained
with anti-insulin and anti-glucagon antibodies (Abcam, Cambridge, UK)
followed by secondary antibodies (AlexaFluor 594, AlexaFluor 488;Jackson ImmunoResearch Laboratories, Baltimore, MD) using standard
techniques.
2.5. Computed Tomography (CT)
Abdominal fat mass were determined by computed tomography
(CT). Brieﬂy, 21-week-old mice (n = 6) of each group were scanned
by using Latheta LCT-200 (Hitachi-Aloka, Tokyo, Japan) while animals
were under 2% isoﬂurane anaesthesia. Adipose tissue mass in the ab-
dominal region between the proximal end of lumbar vertebra L1 and
the distal end of L6 was scanned. And the visceral and subcutaneous
fat depots of the area was analysed.
2.6. Biochemical Analyses
Plasma triglycerides (TG), total cholesterol (TC), non-esteriﬁed
fatty acid (NEFA), glucose, insulin, glucagon, aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), tumor necrosis
factor-α (TNFα), ﬁbroblast growth factor 21 (FGF21), ketone body,
glycerol, creatinine and hepatic lipids, ketone body, thiobarbituric
acid-reactive substrates (TBARS) concentrations, and urine 8-hydroxy-
2′-deoxyguanosine (8-OHdG) contents were measured as described
previously (Ni et al., 2015b; Ota et al., 2008).
2.7. GTTs and ITTs
The glucose tolerance test (GTT) was conducted after an overnight
fast, and themicewere then injectedwith 2 g/kg glucose i.p. The insulin
tolerance test (ITT) was performed after a 4-h fast, and mice were
injected with 1 U/kg human insulin i.p.
2.8. Urinary Glucose Extraction
Micewere housed individually inmetabolic cages for 24 h and urine
samples were collected and urine volume was measured. Urinary glu-
cose concentration was determined by glucose C2 test kit (Wako Life
Sciences, Inc. Osaka, Japan).
2.9. Detection of mRNAs and Proteins
Relative quantiﬁcation real-time polymerase chain reaction (PCR)
and Western blot analyses were performed as described previously
(Kitade et al., 2012). Primers used for real-time PCR are shown in Sup-
plementary Table 2, and primary antibodies for Western blotting are
shown in Supplementary Table 3.
2.10. Statistics
Results are reported as the means ± SEM. Differences between the
mean values were assessed using a two-tailed Student's t-test or
ANOVA. P values b0.05 were considered signiﬁcant.
3. Results
3.1. Empagliﬂozin Reduces Weight and Adiposity and Increases UGE in DIO
Mice
C57BL/6J mice were pair-fed the NC, HFD, or HFD containing
empagliﬂozin for 16 weeks. The high-dose of empagliﬂozin suppressed
weight gain (Fig. 1a) independently of food intake (Fig. 1b, Supplemen-
tary Table 4). However, empagliﬂozin dose-dependently increased
water intake (Fig. 1c). The results from the CT scans showed that ab-
dominal fat accumulation was dose-dependently decreased by
empagliﬂozin in theDIOmice (Fig. 1d, e), and theweights of the visceral
and subcutaneous fat depots were consistently decreased by adminis-
tration of empagliﬂozin (Fig. 1f). Additionally, the liver and BATweights
Fig. 1. Empagliﬂozin reduces weight gain in DIOmice. (a) Bodyweights. (b, c) Food and water intake. (d) Representative CT images. (e) Fat mass calculated from CT scans. (f, g) Fat depot
and tissue weights. (h) Urine volume and urinary glucose. Data are presented as means ± SEM, n= 7–9. *P b 0.05, **P b 0.01 vs. NC; #P b 0.05, ##P b 0.01 vs. HFD.
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as the kidney weights increased with both doses of empagliﬂozin (Fig.
1g). The femoral muscle weight was unaffected by empagliﬂozin (Sup-
plementary Fig. 1a, b). Moreover, administration of empagliﬂozin dose-
dependently increased urine volume and UGE (Fig. 1h). The genes
Slc5a1 and Slc5a2, encoding SGLT1 and SGLT2, respectively, were
dose-dependently upregulated in the kidney by empagliﬂozin (Supple-
mentary Fig. 1c). However, plasma creatinine levels, which are an indi-
cator of renal function, were unaffected by empagliﬂozin
(Supplementary Fig. 1d). Taken together, these data indicate that the
weight reduction by empagliﬂozin was largely attributable to decreases
in both visceral and subcutaneous fat depots under pair-fed conditions
and that there was no effect on renal function.
3.2. Empagliﬂozin Ameliorates HFD-induced Insulin Resistance
The high-dose of empagliﬂozin normalized postprandial
hyperglycaemia in the DIOmice (Fig. 2a). The GTT and ITT data showed
that glucose intolerance and insulin resistance were ameliorated by
empagliﬂozin (Fig. 2b, c), and hyperinsulinemia in fed and fasting states
were suppressed (Fig. 2d). Moreover, the expression levels of G6pc and
Pepck, which are involved in EGP, were elevated by empagliﬂozin in the
DIO mice (Supplementary Fig. 2a). Consistent with these ﬁndings,empagliﬂozin increased fasting glucagon levels (Supplementary Fig.
2b), resulting in a reduced ratio of insulin to glucagon (Fig. 2e). The im-
munoﬂuorescence analysis revealed that the number and size of the
pancreatic islets were increased in the DIO mice, whereas they were
dose-dependently decreased by empagliﬂozin (Fig. 2f, g). Finally, we
found the insulin-stimulated phosphorylation of the insulin receptor β
subunit (Tyr1146) and Akt (Ser473) in eWAT, liver, and muscle was in-
creased in the HFD + Empa mice compared to the HFD mice (Supple-
mentary Fig. 2c).
3.3. Empagliﬂozin Increases Energy Expenditure
To assess whole-body energy expenditure, we placed the mice in
open-circuit indirect calorimetry cages after 6 weeks of feeding, before
an evident change in the body mass of HFD-fed mice was observed.
The HFD did not alter VO2, but it signiﬁcantly suppressed VCO2, RER,
and energy expenditure (Fig. 3a–d). Empagliﬂozin-treated mice that
were fed the HFD exhibited consistently higher oxygen consumption
and tended to exhalemore CO2 than theHFD-fed controls, leading to el-
evated energy expenditure (Fig. 3a, b, d) although they displayed simi-
lar RERs (Fig. 3c). These data suggest that empagliﬂozin treatment
enhances the utilization of both sugar and fat under HFD conditions.
Consistent with this increase in energy expenditure, empagliﬂozin
Fig. 2. Empagliﬂozin ameliorates diet-induced insulin resistance. (a) Fed blood glucose levels. (b, c) GTT and ITT. (d) Plasma insulin levels. (e) Ratio of plasma insulin to glucagon levels. (f)
Representative insulin and glucagon-stained pancreas sections. Scale bars= 100 μm. (g) Islet numbers and sizes. Data are presented asmeans± SEM, n=7–9. *P b 0.05, **P b 0.01 vs. NC;
#P b 0.05, ##P b 0.01 vs. HFD.
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(Fig. 3e). These results indicate that empagliﬂozin reduces obesity by in-
creasing energy expenditure.
3.4. Empagliﬂozin Promotes the Browning of Fat in DIO Mice
The increased energy expenditure and body temperature of the
empagliﬂozin-treated, HFD-fed mice suggested an increase in adaptive
thermogenesis. Indeed, empagliﬂozin decreased lipid accumulation
(Fig. 4a), and increased the number of UCP1+ cells in the interscapular
BAT (Fig. 4b, Supplementary Fig. 3a). The mRNA levels of brown fat-selective genes were also signiﬁcantly upregulated by empagliﬂozin
(Fig. 4c). Furthermore, empagliﬂozin increased UCP1 protein levels in
BAT (Fig. 4d). Brown-like adipocytes expressing UCP1, also known as
beige cells, exist in various WAT depots and can contribute to thermo-
genesis (Cohen et al., 2014). The HFD signiﬁcantly decreased UCP1 pro-
tein levels in both eWAT and inguinal WAT (iWAT) compared with NC,
and these levels were restored by empagliﬂozin (Fig. 4d). Consistent
with the immunoblottingdata, empagliﬂozin also increased the number
of UCP1+ cells in both eWAT and iWAT (Supplementary Fig. 3b, c). Ad-
ditionally, the mRNA levels of beige-selective genes were increased in
iWAT (Supplementary Fig. 3d). Thus, empagliﬂozin appears to promote
Fig. 3. Empagliﬂozin increases energy expenditure in DIO mice. (a) Oxygen consumption (VO2). (b) Carbon dioxide production (VCO2). (c) Respiratory exchange ratio (RER). (d) Energy
expenditure. (e) Rectal temperature. Data are presented as means ± SEM, n= 7–9. *P b 0.05, **P b 0.01 vs. NC; #P b 0.05, ##P b 0.01 vs. HFD.
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mice.
3.5. Empagliﬂozin Activates AMP-activated Protein Kinase and Enhances
Fatty Acid Oxidation in Skeletal Muscle
Empagliﬂozin suppressedHFD-induced TG accumulation, associated
with the upregulated mRNA expression of fatty acid β-oxidation genes
in skeletal muscle (Fig. 5a, b). Furthermore, empagliﬂozin increased
the urinary excretion of ketone bodies and their plasma levels (Fig.
5c). The phosphorylation of AMP-activated protein kinase (AMPKα; at
Thr172) and acetyl-CoA carboxylase (ACC; at Ser79) was increased by
empagliﬂozin (Fig. 5d), suggesting that empagliﬂozin activates AMPK
and enhances fat oxidation in skeletal muscle.
3.6. Empagliﬂozin Attenuates Obesity-induced Inﬂammation in WAT
We next evaluated the effects of empagliﬂozin on adipose tissue bi-
ology. The mean adipocyte size in eWAT was increased 2.5-fold in the
HFD group, and this increase was signiﬁcantly suppressed by
empagliﬂozin (Fig. 6a, b). ThemRNA levels of fatty acid synthesis-relat-
ed geneswere consistently decreased by empagliﬂozin (Fig. 6d). In con-
trast, the mRNA levels for of fatty acid β-oxidation-related genes were
increased by empagliﬂozin (Fig. 6d). The obesity-associated aberrant
expression of adipokines, such as leptin and adiponectin, was also im-
proved by empagliﬂozin (Fig. 6e).
According to the immunostaining and mRNA expression of F4/80,
empagliﬂozin markedly decreased the inﬁltration of macrophages into
the hypertrophic adipose tissue and crown-like structures (Fig. 6a, c,
and f), and iWAT (Supplementary Fig. 4a) of the DIO mice. The levels
of inﬂammatory chemokines and cytokines derived from M1macrophages were decreased in the eWAT of the HFD + Empa mice
(Fig. 6f). The plasma levels of TNFα were markedly lower in the HFD
+ Empa mice than in the HFD mice (Fig. 6g). In contrast, empagliﬂozin
upregulated the mRNA levels of the anti-inﬂammatory and M2
macrophage markers (Fig. 6h). Empagliﬂozin also attenuated the
phosphorylation of JNK and ERK1/2, although the phosphorylation
levels of p38 MAPK and NF-κB p65 were comparable among the
treatment groups (Fig. 6i, Supplementary Fig. 4b). Furthermore, the in-
crease in endoplasmic reticulum stress in the DIO mice, as assessed by
GRP78 and CHOP protein levels, as well as spliced XBP1(sXBP1) and
Grp78 mRNA expression, was suppressed by empagliﬂozin (Fig. 6i,
Supplementary Fig. 4b, c).
The levels of urinary 8-OHdG, a marker of oxidized DNA damage,
were increased, but empagliﬂozin decreased the levels markedly (Fig.
6j). Empagliﬂozin also suppressed the levels of TBARS, an indicator of
lipid peroxidation, in eWAT and plasma by 35.3% and 28.7%, respective-
ly (Fig. 6j). These ﬁndings were observed in association with decreased
mRNA expression of the subunits of NADPH oxidase (Supplementary
Fig. 4d) and increased mRNA expression of anti-oxidative stress genes
in the eWAT of the DIO mice (Supplementary Fig. 4e).
3.7. Empagliﬂozin Protects Mice from Diet-induced Hepatic Steatosis and
Inﬂammation
The histological analysis revealed severe lipid accumulation in the
livers of the mice fed the HFD, which was decreased markedly by
empagliﬂozin (Fig. 7a). Empagliﬂozin consistently reduced the liver
TG, TC, andNEFA levels in the HFD-fedmice (Fig. 7b), and theseﬁndings
were associated with the suppression of lipogenic gene expression and
the upregulation of mitochondrial fatty acid β-oxidation genes (Fig. 7c).
Moreover, the changes in plasma glycerol levels induced by lipolysis
Fig. 4. Empagliﬂozin increases UCP1 levels in BAT and beige fat. (a) H&E-stained BAT sections. Scale bars = 100 μm. (b) UCP1-stained BAT sections. Scale bars = 100 μm. (c) mRNA
expression of brown fat-related genes. (d) Immunobloting and quantitation of UCP1 in BAT, eWAT and iWAT. Data are presented as means ± SEM, n = 7–9. *P b 0.05, **P b 0.01 vs.
NC; #P b 0.05, ##P b 0.01 vs. HFD.
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Fig. 5. Empagliﬂozin enhances fat utilization in skeletal muscle. (a) Muscle TG content. (b) mRNA expression of fatty acid oxidation-related genes. (c) Urinary ketone body and fasting
plasma ketone body concentrations. (d) Immunoblotting of skeletalmuscle lysates. Data are presented as means± SEM, n=7–9. *P b 0.05, **P b 0.01 vs. NC; #P b 0.05, ##P b 0.01 vs. HFD.
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istration of empagliﬂozin caused an elevation in the levels of hepatic ke-
tone bodies (Supplementary Fig. 5a) but decreased the levels of plasma
AST andALT; plasma lipid levelswere not signiﬁcantly affected (Supple-
mentary Table 4).
As withWAT, empagliﬂozin also markedly decreased the number of
F4/80+ cells (Fig. 7d, e, Supplementary Fig. 5b) and the mRNA expres-
sion of proinﬂammatory cytokines and chemokines in the liver (Fig.
7e), whereas it increased the mRNA levels of anti-inﬂammatory and
M2 macrophage markers (Fig. 7f). These changes were associated
with attenuated phosphorylation of NF-κB p65 and JNK and reduced
CHOP expression in the liver (Fig. 7g, Supplementary Fig. 5c). Further-
more, the TBARS levels and gene expression of the NADPH oxidase sub-
unitswere decreased in theHFD+Empa group comparedwith the HFD
group (Fig. 7h, Supplementary Fig. 5d). However, empagliﬂozin in-
creased the mRNA levels of anti-oxidative stress genes (Supplementary
Fig. 5e). Furthermore, the hepatic mRNA levels of ﬁbroblast growth fac-
tor (FGF21) and the plasma levels of FGF21 were increased by
empagliﬂozin in the DIO mice (Fig. 7i). These data suggest that FGF21
can mediate a shift of energy metabolism towards fat utilization in re-
sponse to SGLT2 inhibition.
3.8. Reciprocal Decreases in M1 Macrophages and Increases in M2 Macro-
phages in Empagliﬂozin-fed Mice
To further quantify the adipose tissue macrophages (ATMs) and he-
patic macrophage/Kupffer cell subsets, FACS was used to analyse the
immune cells isolated from the mice. The increase in the total number
of ATMs associated with HFD feeding was decreased slightly by
empagliﬂozin (Fig. 8a, c), and the HFD-fed mice exhibited signiﬁcantly
higher M1 and lower M2 expression levels within the ATMs. The high-
dose of empagliﬂozin caused a 49% decrease in M1 ATMs and a 3.3-
fold increase in M2 ATMs compared with HFD feeding, resulting inmacrophage polarization towards an anti-inﬂammatory phenotype
(Fig. 8b, c).
Moreover, the total number of liver macrophages (LMs) was in-
creased in the mice fed the HFD compared with the NC diet (Fig. 8d,
f). In addition to the reduction in total LM content, the empagliﬂozin-
treated mice had fewer M1 LMs and more M2 LMs than the HFD-fed
mice, resulting in macrophage polarization towards an anti-inﬂamma-
tory phenotype in the liver (Fig. 8e, f). Moreover, the total number of
CD3+, CD4+, and CD8+ T cells in the eWAT and liver increased with
HFD feeding, but this effectwas signiﬁcantly decreased by empagliﬂozin
(Supplementary Fig. 6a–d). These results suggest that empagliﬂozin
causes a shift to an M2-dominant macrophage phenotype and reduces
T cell accumulation in the liver and WAT, contributing to the attenua-
tion of obesity-induced insulin resistance and inﬂammation.
4. Discussion
The present study provides evidence that SGLT2 inhibition is associ-
atedwith the substantial impacts of empagliﬂozin on energy homeosta-
sis, obesity-induced inﬂammation, and insulin resistance. Several
studies have demonstrated the protective effects of SGLT2 inhibitors
against obesity in rodents. In 8-week-old pair-fed animals, tofogliﬂozin
suppressedHFD-inducedweight gain and hepatic steatosis (Obata et al.,
2016). In contrast, 4 weeks of treatment with remogliﬂozin following
11 weeks of HFD feeding attenuated hepatic steatosis without affecting
weight gain (Nakano et al., 2015). Another report showed that
luseogliﬂozin decreased liver weight and ameliorated steatohepatitis
in streptozotocin-treated mice that were fed a HFD, and it did so with-
out altering weight gain (Qiang et al., 2015). However, the effects of
SGLT2 inhibition on energy homeostasis and obesity-related inﬂamma-
tion remain largely unknown. Because SGLT2 inhibitors have been
shown to augment food intake in rodents (Devenny et al., 2012; Obata
et al., 2016),we pair-fed themice to clarify the effect of SGLT2 inhibition
Fig. 6. Empagliﬂozin attenuates adipose tissue inﬂammation. (a) F4/80 immunostaining in eWAT. Scale bars=100 μm. (b) Adipocyte sizes. (c) The F4/80+-cell ratio. (d)mRNA expression
of lipometabolic-related genes. (e) mRNA expression of adipocytokine genes. (f) mRNA expression of F4/80 and inﬂammatory cytokines and chemokines. (g) Plasma levels of TNFα.
(h) mRNA expression of M2 marker genes. (i) Immunoblotting of eWAT lysates. (j) Urinary 8-OHdG levels and TBARS content in eWAT and plasma. Data are presented as means ±
SEM, n= 7–9. *P b 0.05, **P b 0.01 vs. NC; #P b 0.05, ##P b 0.01 vs. HFD.
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Fig. 7. Empagliﬂozin ameliorates hepatic steatosis and inﬂammation. (a) H&E-stained liver sections. Scale bars= 100 μm. (b) Hepatic lipid content. (c) mRNA levels of lipogenic regulator
genes. (d) F4/80 immunostaining. Scale bars = 100 μm. (e) mRNA expression of F4/80 and inﬂammatory cytokines and chemokines. (f) mRNA expression of M2 marker genes.
(g) Immunoblotting of liver lysates. (h) TBARS content. (i) mRNA expression of FGF21 in the liver and plasma levels of FGF21. Data are presented as means ± SEM, n= 7–9. *P b 0.05,
**P b 0.01 vs. NC; #P b 0.05, ##P b 0.01 vs. HFD.
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Fig. 8. Empagliﬂozin treatment leads to a predominance of M2 macrophage populations over M1 in the WAT and liver. (a) Representative plots of total ATMs in eWAT. (b) M1 and M2
macrophages in eWAT. (c) Quantitation of total counts of ATMs, M1 ATMs, and M2 ATMs and M1/M2 ratios. (d) Representative plots of total LMs. (e) M1 and M2 macrophages in the
liver. (f) Quantitation of total counts of LMs, M1 LMs, and M2 LMs and M1/M2 ratios. Data are presented as means ± SEM, n = 7–9. *P b 0.05, **P b 0.01 vs. NC; #P b 0.05, ##P b 0.01
vs. HFD.
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147L. Xu et al. / EBioMedicine 20 (2017) 137–149on obesity and its comorbidities. Notably, empagliﬂozin reduced adi-
posity via increased energy expenditure and caloric loss due to
glucosuria. Notable weight loss, particularly in HFD + Hi Empa group,
could contribute to the amelioration of obesity-related insulin resis-
tance and metabolic phenotype. The relative expression levels of
Slc5a1 and Slc5a2 in the kidney were increased, possibly due to a com-
pensatory response to SGLT2 inhibition, as previously reported (Rieg
et al., 2014).
Although the present study revealed that increased UGE drove re-
ductions in adiposity and ectopic fat, these ﬁndings may be limited be-
cause the effects of empagliﬂozin were evaluated using preventative
treatments rather than a therapeutic study design. Additional therapeu-
tic studies will aid in the translation of experimental results regarding
the anti-obesity effects of SGLT2 inhibitors to clinical settings. The dif-
ferences among the clinical doses of empagliﬂozin used for humans
(10 and 25 mg/d) and the experimental doses used for rats
(3 mg/kg/d) (Thomas et al., 2012) and mice (3 and 10 mg/kg/d) in the
present study may reﬂect differences in the pharmacokinetic parame-
ters between humans and rodents. The linear pharmacokinetics of
empagliﬂozin indicate that the maximum plasma concentration
(Cmax) after 3mg/kg of this drug is administered can be estimated as ap-
proximately 500 nM; even if a 10-fold higher concentration is assumed
to be present in the kidney, thiswould still be below the apparentKi (in-
hibition constant; 8500 nM) of empagliﬂozin for SGLT-1 (Grempler et
al., 2012). Therefore, the relevant inhibition of human, mouse, or rat
SGLT-1 by pharmacological doses of empagliﬂozin would not be
expected.
Pharmacologically induced glucosuria leads to adaptive responses in
glucose homeostasis and hormone release, and the genetic or pharma-
cological inhibition of SGLT2 has beneﬁcial effects on hyperinsulinemia
and hyperglycaemia (Tahara et al., 2013; Vallon et al., 2013). Converse-
ly, SGLT2 inhibition induces EGP in mice (Bonner et al., 2015; Neschen
et al., 2015). In patients with type 2 diabetes, SGLT2 inhibitors also in-
crease EGP and plasma glucagon levels, as well as decrease plasma glu-
cose and insulin levels (Ferrannini et al., 2014;Merovci et al., 2014). The
empagliﬂozin-induced hormonal change in relative hyperglucagonemia
can be explained by reductions in glycaemia and insulin release, as insu-
lin normally restrains glucagon secretion via paracrine action
(Maruyama et al., 1984). Moreover, a recent study suggested that the
inhibition of SGLT2with dapagliﬂozin directly triggered glucagon secre-
tion in pancreatic alpha-cells (Bonner et al., 2015). Our study conﬁrmed
that empagliﬂozin induced the expression of genes involved in hepatic
glucose production and glucagon release and reduced the ratio of insu-
lin to glucagon.Moreover, empagliﬂozin decreased the number and size
of pancreatic islets, although it did not alter alpha-cell mass. These re-
sults suggest that the suppression of hyperinsulinemia by empagliﬂozin
causes relative hyperglucagonemia and increases EGP. This relative
hyperglucagonemia may promote lipolysis, contributing to fat utiliza-
tion and the release of ketone bodies in DIO mice.
Consistent with previous reports demonstrating the anti-obesity ef-
fects of SGLT2 inhibitors (Devenny et al., 2012; Nakano et al., 2015;
Yokono et al., 2014), we found that the administration of empagliﬂozin
mitigated HFD-induced weight gain and fatty liver changes. Our ﬁnd-
ings suggest anunderlyingmechanism for theweight reduction that de-
pends partially on increased energy expenditure and enhanced fatty
acid oxidation. In our study, empagliﬂozin enhances the phosphoryla-
tion of AMPKα and ACC in skeletal muscle. A recent study found that
canagliﬂozin activates AMPK in vitro and lowers liver lipid content
(Hawley et al., 2016). Once activated, AMPK acts to restore energy ho-
meostasis by promoting catabolic pathways, including fatty acid oxida-
tion, while inhibiting anabolic pathways, including fatty acid synthesis
(Hardie, 2014; Hardie et al., 2016). Adiponectin activates AMPK via
adiponectin receptor 1 in skeletal muscle (Yamauchi and Kadowaki,
2008). Moreover, the inhibition of SGLT2 increases energy expenditure,
leading to the increase of AMP/ATP (Gowans et al., 2013). Therefore, the
potential mechanisms of activation of AMPK by empagliﬂozin are, atleast in part, via increased adiponectin expression inWAT and elevation
of AMP/ATP. Because the phosphorylation of ACC by AMPK is known to
lower muscle lipid content, our results suggest a potential beneﬁt of
empagliﬂozin and other SGLT2 inhibitors in protecting against obesity
or ectopic fat accumulation. In the present study, the low dose of
empagliﬂozin tended to increase the phosphorylation levels of ACC
and AMPK, which contributed to the decreases in ectopic fat in the
liver and muscle in the absence of weight reduction.
An important ﬁnding of this study is that empagliﬂozin increases
whole-body energy expenditure, and the protein levels of UCP1 in
both BAT andWAT. These data suggest that empagliﬂozin promotes ad-
ipose tissue browning. Recent studies have demonstrated that M2-po-
larized macrophages play a key role in the browning of WAT via the
activation of type 2 cytokine production during cold exposure
(Nguyen et al., 2011; Qiu et al., 2014). In response to cold exposure, var-
ious cytokines are released from M2-type macrophages; these include
catecholamines, which activate β-adrenergic receptors in adipocytes
to turn on the thermogenic program, including the induction of UCP1.
Moreover, adiponectin plays a role in promoting beige adipocytes
(Hui et al., 2015). We found that empagliﬂozin causes M2 polarization
in macrophages and increases adiponectin levels in WAT, which can
lead to adipose tissue browning.
FGF21 has emerged as a key mediator of metabolic processes and
contributes to the regulation of lipolysis in WAT (Inagaki et al., 2007),
and the increase in fatty acid oxidation in the liver (Badman et al.,
2007). FGF21 also activates the β3-adrenergic receptor inWAT and reg-
ulates the recruitment of beige adipocytes (Fisher et al., 2012). The sys-
temic administration of FGF21 leads to weight loss in obese mouse
models through increases in energy expenditure (Kharitonenkov et al.,
2005). Thus, increased FGF21 in the liver and circulation following
empagliﬂozin administrationmay be another factor promoting fat utili-
zation and browning under the conditions of obesity.
Obesity or ectopic fat accumulation induces an innate immune re-
sponse with the subsequent recruitment of immune cells, which ulti-
mately leads to the development of insulin resistance and non-
alcoholic steatohepatitis (NASH). In particular,macrophage recruitment
and polarization are pivotal to obesity-induced inﬂammation and insu-
lin resistance (Lumeng et al., 2007; Weisberg et al., 2003). Thus, strate-
gies to restrain M1 polarization and/or drive the alternative M2
activation of macrophagesmay have the potential to protect against ex-
acerbated inﬂammation and insulin resistance and may even attenuate
the progression to NASH (Odegaard et al., 2007; Patsouris et al., 2008;
Wan et al., 2014). Our results indicate that empagliﬂozin attenuates
obesity-related inﬂammation by decreasing macrophage accumulation
and causing an M2-dominant phenotypic shift of macrophages in the
WAT and liver. Additionally, the inﬁltration of Th1 and CD8+ T cells pre-
cedes M1-polarized macrophage recruitment, and the interactions be-
tween the T cells and macrophages constitute a maladaptive feed-
forward loop that leads to adipose inﬂammation and insulin resistance
(Nishimura et al., 2009; Sell et al., 2012). Consequently, empagliﬂozin
may reduce the accumulation of T cells and M1 macrophages and in-
crease the amount ofM2macrophages to alleviate inﬂammation and in-
sulin resistance in obesity. The loss of glucose calories induced by
empagliﬂozin is consistent with increased lipid mobilization, causing a
reduction in fat mass and weight (Ferrannini et al., 2016; Ferrannini et
al., 2014). Thus, the anti-inﬂammatory effects of empagliﬂozin in the
WAT and liver may be attributable to its impact on reducing both adi-
posity and hepatic steatosis.
In conclusion, the present study identiﬁed a potentialmechanism by
which SGLT2 inhibitors reduce obesity and control whole-body energy
homeostasis. Empagliﬂozin-mediated SGLT2 inhibition enhances fat
utilization and browning and attenuates obesity-induced inﬂammation
and insulin resistance via M2 or alternative macrophage activation.
Overall, the current investigation highlights the potential clinical utility
of SGLT2 inhibition in the prevention of obesity and related metabolic
disorders, such as insulin resistance, NAFLD, and type 2 diabetes.
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